We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type |
---|---|---|---|
Applied Genetic Technologies Corporation | NASDAQ:AGTC | NASDAQ | Common Stock |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
0.00 | 0.00% | 0.3936 | 0.4329 | 0.3739 | 0 | 01:00:00 |
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
PURSUANT TO SECTION 13 OR 15(D)
OF THE SECURITIES EXCHANGE ACT OF 1934
Date of Report (Date of earliest event reported): November 30, 2021
APPLIED GENETIC TECHNOLOGIES CORPORATION
(Exact Name of Registrant as Specified in Charter)
Delaware | 001-36370 | 59-3553710 | ||
(State or other jurisdiction of incorporation) |
(Commission File Number) |
(IRS Employer Identification Number) |
14193 NW 119th Terrace
Suite 10
Alachua, Florida, 32165
(Address of principal executive offices) (Zip Code)
(386) 462-2204
(Registrant’s telephone number, including area code)
Not Applicable
(Former Name or Former Address, if Changed Since Last Report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below).
☐ |
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
☐ |
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
☐ |
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
☐ |
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
Securities registered pursuant to Section 12(b) of the Act:
Title of each class |
Trading
|
Name of each exchange
|
||
Common Stock, $0.001 par value | AGTC | Nasdaq Global Market |
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company ☐
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Item 5.02. |
Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers |
On November 30, 2021, Applied Genetic Technologies Corporation (the “Company”) appointed James Robinson to serve on its board of directors as a Class I director. His term will expire at the Company’s Annual Meeting of Stockholders for fiscal year 2024. Mr. Robinson was also appointed to serve on the Company’s audit committee and nominating and corporate governance committee.
In connection with his appointment as a non-employee director, Mr. Robinson received a stock option to purchase 25,000 shares of the Company’s common stock at $2.17 per share on the date of his election, which will vest one third on the first anniversary of the date of grant and thereafter in 24 equal monthly installments, so that the option is fully-vested on the third anniversary of the date of grant, and has a term of ten years. He will also receive cash and equity compensation pursuant to the Company’s non-employee director compensation program. In addition, the Company has entered into an indemnification agreement with Mr. Robinson in connection with his appointment to the Board, which is in substantially the same form as that entered into with the other directors of the Company.
The Company issued a press release announcing Mr. Robinson’s appointment to its board of directors, which is attached as Exhibit 99.1 to this current report.
Item 5.07. |
Submission of Matters to a Vote of Security Holders. |
The Company held its 2022 Annual Meeting of Stockholders on November 30, 2021, at which three proposals were submitted to, and approved by, its stockholders. The holders of 24,412,931 shares of common stock of the Company were present or represented by proxy at the meeting. The proposals are described in detail in the Company’s definitive proxy statement for the 2022 Annual Meeting of Stockholders filed with the Securities and Exchange Commission on October 15, 2021. The final results for the votes for each proposal are set forth below.
Each of Scott Koenig, Yehia Hashad and Ivana Magovcevic-Liebisch was elected as a Class II Director of the Company, to serve a three-year term expiring at the 2025 Annual Meeting of Stockholders. The votes cast in the election of the directors were as follows:
Nominee |
Votes For | Votes Withheld |
Broker
Non-Votes |
|||
Scott Koenig |
6,827,676 | 4,352,719 | 13,232,536 | |||
Yehia Hashad |
10,406,801 | 773,594 | 13,232,536 | |||
Ivana Magovcevic-Liebisch |
10,403,782 | 776,613 | 13,232,536 |
The Company’s stockholders approved, on an advisory basis, the compensation paid to the named executive officers of the Company. The votes cast on this proposal were as follows:
Proposal |
Votes For | Votes Against | Abstentions |
Broker
Non-Votes |
||||
To approve, on an advisory basis, the compensation paid to our named executive officers | 9,783,196 | 1,152,958 | 244,241 | 13,232,536 |
The Company’s stockholders also approved the proposal to ratify the appointment of Ernst & Young LLP as its independent registered public accounting firm for its fiscal year ending June 30, 2022. The votes cast on this proposal were as follows:
Proposal |
Votes For | Votes Against | Abstentions |
Broker
Non-Votes |
||||
To ratify the appointment of Ernst & Young LLP as the Company’s independent registered public accounting firm for fiscal year 2022 | 23,989,385 | 279,192 | 144,354 | — |
2
Item 9.01. |
Financial Statements and Exhibits. |
(d) Exhibits.
Exhibit No. |
Description |
|
99.1 | Press release dated December 6, 2021, entitled “AGTC Appoints Biopharmaceutical Industry Leader James Robinson to its Board of Directors.” | |
104 | The cover page from this Current Report on Form 8-K, formatted in Inline XRBL |
3
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.
APPLIED GENETIC TECHNOLOGIES CORPORATION |
||
By: |
/s/ Susan B. Washer |
|
Susan B. Washer | ||
President and Chief Executive Officer |
Date: December 6, 2021
4
1 Year Applied Genetic Technolo... Chart |
1 Month Applied Genetic Technolo... Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions